



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

February 26, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – February 24, 2021

TOTAL Cases Reported Since 1/22/20

28,138,938

NEW Cases Reported to CDC on 2/24/21

74,806

Change in 7-Day Case Average

-13.5%


Current 7-Day Case Average (2/18/21 - 2/24/21)

66,348

Prior 7-Day Case Average (2/11/21 - 2/17/21)

76,741

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	315,179 (1/8/21)	249,303 (1/11/21)
2nd Peak	75,119 (7/17/20)	67,316 (7/23/20)
1st Peak	42,550 (4/6/20)	31,936 (4/12/20)



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – February 23, 2021

Patients Currently Hospitalized with COVID on 2/23/21

50,183

New Admissions on 2/23/21

6,562

Peak in New Admissions (1/5/21)

18,006

Change in 7-Day Average of New Admissions


-11.3%

Current 7-Day Average of New Admissions (2/17/21 - 2/23/21)

6,431

Prior 7-Day Average of New Admissions (2/10/21 - 2/16/21)

7,250



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – February 24, 2021

TOTAL Deaths Reported Since 1/22/2020

503,587

NEW Deaths Reported to CDC on 2/24/21

2,407

Change in 7-Day Death Average

-23.8%

Current 7-Day Death Average (2/18/21 - 2/24/21)


2,047

Prior 7-Day Death Average (2/11/21 - 2/17/21)

2,687


Forecasted Total Deaths by 3/20/21

526,000-548,000





WEAR A MASK



STAY 6 FEET APART












AVOID CROWDS



AVOID TRAVEL

Selected COVID-19 Vaccines

Platform		Developer		Status
Nucleic Acid (mRNA)			■ 94% efficacy vs. symptomatic disease	→ EUA
			■ 95% efficacy vs. symptomatic disease	→ EUA
Adenovirus Vector			■ 72% efficacy in U.S. 85% efficacy overall vs. severe disease in U.S., South Africa, Latin America	→ EUA review Feb. 26
			■ 63% efficacy vs. symptomatic disease in U.K., Brazil and South Africa	→ EUA TBD
Recombinant Protein and Adjuvant			■ Phase 2 starts	→ Feb. 2021
			■ 89% efficacy vs. symptomatic disease in U.K.	→ EUA TBD

Selected SARS-CoV-2 Variants of Concern

Lineage

Characteristics

B.1.1.7 (originally **United Kingdom**)

- Increased transmissibility
- Possibly increased disease severity
- Covered well by currently authorized vaccines

B.1.351 (originally **South Africa**)

- Possibly increased transmissibility
- **Moderately to severely** reduced vaccine efficacy
- *In vitro* studies suggest neutralization by certain monoclonal antibodies may be **severely** reduced

P.1 (originally **Brazil**)

- Antibodies elicited by previous infection or vaccine may be less effective

Moderna To Begin Clinical Trials of COVID Booster Shots for Variant From South Africa, Sends to NIH for Study

Variant Vaccine Strategy – Upcoming NIAID Clinical Trial in Collaboration with Moderna

- Moderna has developed a variant-specific vaccine candidate **mRNA-1273.351** against the variant known as **B.1.351** first identified in the Republic of South Africa
- NIAID and Moderna will conduct a phase 1 study of the safety and immunogenicity of **mRNA-1273.351** in naïve and previously vaccinated adults
- Planned study launch: mid-March 2021



Planned NIAID Trial (DMID 21-0002): Two Cohorts

Cohort 1 (previously vaccinated volunteers)

- Volunteers in Seattle and Atlanta who were vaccinated a year ago in the Phase 1 Moderna vaccine trial
 - Arm 1a participants (n=30) will receive 50mcg booster dose of mRNA-1273.351
 - Arm 1b participants (n=30) will receive 25mcg each of both mRNA-1273 and mRNA-1273.351
- Investigators will compare virus neutralization of the original SARS-CoV-2 strain and the B.1.351 variant

Cohort 2 (unvaccinated and not previously infected volunteers)

- Volunteers (n=150) in Seattle, Atlanta, Cincinnati, and Nashville
- Volunteers will be randomized to 6 different prime/boost vaccine strategies using different combinations of mRNA-1273 and mRNA-1273.351
- Investigators will compare virus neutralization against both the original strain and the B.1.351 variant among the groups





THE WHITE HOUSE
WASHINGTON

WH.GOV